story of the week
Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
Lancet Neurol 2024 Oct 01;23(10)1013-1024, JA Allen, J Lin, I Basta, T Dysgaard, C Eggers, JT Guptill, KG Gwathmey, C Hewamadduma, E Hofman, YM Hussain, S Kuwabara, G Le Masson, F Leypoldt, T Chang, M Lipowska, M Lowe, G Lauria, L Querol, MA Simu, N Suresh, A Tse, P Ulrichts, B Van Hoorick, R Yamasaki, RA Lewis, PA van DoornFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.